Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hamid Emamekhoo

Showing results (61-70 of 61) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 61 results.
The Lancet. Oncology|June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 studyMohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
Pageof 7

Showing results (61-70 of 61) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 61 results.
The Lancet. Oncology|June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 studyMohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
Pageof 7